Base-case results and PSA (United Kingdom health care perspective)
| Strategy . | Cost (95% CI) (UK pound) . | Incremental cost (95% CI) (UK pound) . | Effectiveness (95% CI) (QALY) . | Incremental effectiveness (95% CI) (QALY) . | INMB (95% CI) (UK pound/QALY) . | % Cost-effectiveness at WTP threshold of $20 000 . | % Cost-effectiveness at WTP threshold of $30 000 . |
|---|---|---|---|---|---|---|---|
| United Kingdom model (lifetime horizon) | |||||||
| Upfront HSCT | £335 800 (£303 700-£369 800) | £215 300 (£152 300-£270 600) | 9.74 (8.75-10.72) | 0.84 (−0.39 to 2.16) | £235 600 (£166 800-£298 500) | 100 | 100 |
| Delayed HSCT | £551 100 (£487 000-£609 000) | 8.90 (8.01-9.70) | 0 | 0 | |||
| INMB at thresholds of £20 000 and £30 000 per QALY (95% CI) £187 200 (£164 000-£287 300) and £235 600 (£166 800-£298 500) | |||||||
| United Kingdom model (10-year horizon) | |||||||
| Upfront HSCT | £231 900 (£208 000-£256 800) | £120 100 (£83 900-£148 600) | 4.74 (4.40-5.08) | 0.30 (−0.18 to 0.82) | £127 300 (£89 800-£158 600) | 100 | 100 |
| Delayed HSCT | £352 000 (£313 500-£384 000) | 4.44 (4.01-4.83) | 0 | 0 | |||
| INMB at thresholds of £20 000 and £30 000 per QALY (95% CI) £187 200 (£164 000-£287 300) and £235 600 (£166 800-£298 500) | |||||||
| Strategy . | Cost (95% CI) (UK pound) . | Incremental cost (95% CI) (UK pound) . | Effectiveness (95% CI) (QALY) . | Incremental effectiveness (95% CI) (QALY) . | INMB (95% CI) (UK pound/QALY) . | % Cost-effectiveness at WTP threshold of $20 000 . | % Cost-effectiveness at WTP threshold of $30 000 . |
|---|---|---|---|---|---|---|---|
| United Kingdom model (lifetime horizon) | |||||||
| Upfront HSCT | £335 800 (£303 700-£369 800) | £215 300 (£152 300-£270 600) | 9.74 (8.75-10.72) | 0.84 (−0.39 to 2.16) | £235 600 (£166 800-£298 500) | 100 | 100 |
| Delayed HSCT | £551 100 (£487 000-£609 000) | 8.90 (8.01-9.70) | 0 | 0 | |||
| INMB at thresholds of £20 000 and £30 000 per QALY (95% CI) £187 200 (£164 000-£287 300) and £235 600 (£166 800-£298 500) | |||||||
| United Kingdom model (10-year horizon) | |||||||
| Upfront HSCT | £231 900 (£208 000-£256 800) | £120 100 (£83 900-£148 600) | 4.74 (4.40-5.08) | 0.30 (−0.18 to 0.82) | £127 300 (£89 800-£158 600) | 100 | 100 |
| Delayed HSCT | £352 000 (£313 500-£384 000) | 4.44 (4.01-4.83) | 0 | 0 | |||
| INMB at thresholds of £20 000 and £30 000 per QALY (95% CI) £187 200 (£164 000-£287 300) and £235 600 (£166 800-£298 500) | |||||||
Costs have been rounded to the nearest hundred.